论文部分内容阅读
全球有高血压病患者18亿,我国高血压病患者已超过1亿。高血压病不但发病率高,也是心脑血管疾病的重要危险因素。重症高血压易出现靶器官损害,导致危及生命的事件发生。因此用于治疗高血压的费用也是相当可观。如果选择疗效好、安全性好、费用低的治疗,不但可以降低高血压治疗的直接费用,相对也减少了间接费用。本文对进口尼卡地平注射液及国产尼卡地平注射液3种不同治疗方案进行了成本-效果分析,以期为临床治疗急症高血压合理使用尼卡地平注射液提供参考。
There are 1.8 billion hypertensive patients in the world, and there are more than 100 million hypertensive patients in our country. Not only the high incidence of hypertension is also an important risk factor for cardiovascular and cerebrovascular diseases. Severe high blood pressure prone to target organ damage, leading to life-threatening events. Therefore, the cost of treating hypertension is also considerable. If you choose a good effect, good security, low-cost treatment, not only can reduce the direct costs of treatment of hypertension, but also reduce the overhead costs. In this paper, the cost-effect analysis of three different treatment regimens of imported nicardipine injection and domestic nicardipine injection was conducted in order to provide a reference for the rational use of nicardipine injection in the treatment of acute hypertension.